TLSI
TriSalus Life SciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The better read-through from Q1 is that the core platform still showed 86.2% gross margin, cash rose to $56.6 million after the $46 million raise, and management kept layering real-world PEDD evidence plus a visible second-half data calendar. If the commercial reset was genuinely temporary and TriNav Advance clears in 2H26, the current equity value leaves room for a sharper rerating than a normal medtech quarter would imply [#PR-2026-05-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
2026 revenue guidance was reduced to $54 million-$57 million after Q1 revenue of $8.9 million missed the prior growth trajectory.
Momentum
89
Value
41
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $4.75 · Bear $1.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.30
Why
Momentum89 · Δ7d -
Value41 · Δ7d +0.1
Sentiment40 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
40
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 88.8 / Value 41.1 / Sentiment 39.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$225.4M
Beta
0.43
Shares Out
49.96M
P/E (TTM) · Derived
-3.4
P/S (TTM)
7.59
P/FCF (TTM) · Derived
-6.72
Rev YoY
+57.4%
EPS YoY
-693.4%
Gross Margin
+84.0%
Op Margin
-77.7%
Net Debt
$13.66M
Current Ratio
3.05
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology